argenex SE $ARGX Holdings Raised by Optiver Holding B.V.

Optiver Holding B.V. lifted its stake in argenex SE (NASDAQ:ARGX) by 907.0% in the first quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 10,110 shares of the company’s stock after purchasing an additional 9,106 shares during the quarter. Optiver Holding B.V.’s holdings in argenex were worth $7,383,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors have also recently bought and sold shares of the company. AQR Capital Management LLC lifted its stake in argenex by 32.1% during the first quarter. AQR Capital Management LLC now owns 502 shares of the company’s stock valued at $297,000 after buying an additional 122 shares in the last quarter. NewEdge Advisors LLC raised its holdings in shares of argenex by 5,962.5% during the first quarter. NewEdge Advisors LLC now owns 1,455 shares of the company’s stock valued at $862,000 after acquiring an additional 1,431 shares during the period. Focus Partners Wealth lifted its position in shares of argenex by 22.3% in the 1st quarter. Focus Partners Wealth now owns 400 shares of the company’s stock valued at $237,000 after acquiring an additional 73 shares in the last quarter. Geneos Wealth Management Inc. lifted its position in shares of argenex by 550.0% in the 1st quarter. Geneos Wealth Management Inc. now owns 117 shares of the company’s stock valued at $69,000 after acquiring an additional 99 shares in the last quarter. Finally, Northwestern Mutual Wealth Management Co. boosted its stake in argenex by 60.2% in the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 133 shares of the company’s stock worth $73,000 after purchasing an additional 50 shares during the period. Hedge funds and other institutional investors own 60.32% of the company’s stock.

Analyst Ratings Changes

Several equities analysts have weighed in on ARGX shares. Wells Fargo & Company lifted their price objective on shares of argenex from $1,260.00 to $1,291.00 and gave the stock an “overweight” rating in a research report on Monday, June 1st. Bank of America raised their target price on argenex from $1,016.00 to $1,088.00 and gave the stock a “buy” rating in a research report on Thursday, July 2nd. Citigroup lifted their price target on argenex from $1,152.00 to $1,182.00 and gave the company a “buy” rating in a report on Tuesday, July 21st. Royal Bank Of Canada upped their price target on argenex from $945.00 to $1,025.00 and gave the company an “outperform” rating in a research report on Friday, July 24th. Finally, Robert W. Baird increased their price objective on argenex from $867.00 to $932.00 and gave the stock a “neutral” rating in a research note on Monday, July 27th. Two research analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and four have assigned a Hold rating to the company’s stock. According to data from MarketBeat, argenex presently has an average rating of “Moderate Buy” and an average target price of $1,056.89.

argenex Stock Performance

argenex stock opened at $853.82 on Friday. The firm has a market cap of $53.41 billion, a PE ratio of 32.79, a P/E/G ratio of 1.12 and a beta of 0.45. The firm’s 50 day moving average price is $875.66 and its two-hundred day moving average price is $817.63. argenex SE has a twelve month low of $631.47 and a twelve month high of $953.58.

argenex (NASDAQ:ARGX) last released its earnings results on Tuesday, July 21st. The company reported $7.32 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $5.86 by $1.46. The company had revenue of $1.54 billion during the quarter, compared to the consensus estimate of $1.45 billion. argenex had a net margin of 32.19% and a return on equity of 43.59%. Equities analysts anticipate that argenex SE will post 28.05 EPS for the current fiscal year.

argenex Company Profile

argenx (NASDAQ: ARGX) is a biotechnology company focused on the discovery, development and commercialization of antibody-based therapeutics for severe autoimmune and neuromuscular diseases. The company uses its proprietary SIMPLE Antibody platform to generate differentiated antibodies and engineered Fc regions, and it pursues mechanisms that modulate the neonatal Fc receptor (FcRn) to reduce pathogenic IgG levels. Argenx’s research and development activities span target identification, preclinical development and late-stage clinical programs aimed at addressing unmet needs in immunology.

The company’s lead product, efgartigimod (marketed as Vyvgart), is an FcRn antagonist developed to reduce circulating IgG antibodies and treat IgG-mediated disorders.